Aspen says it has received two unsolicited offers to buy parts of its global active pharmaceutical ingredients (API) business, which manufacturers active ingredients used in medications. Its share price leapt the most in more than four months.

The manufacturing business has operations in SA, the Netherlands and the US, the company said. The offer excluded a French manufacturing facility that also produces APIs...

This article is free to read if you register or sign in.

If you have already registered or subscribed, please sign in to continue.

Questions or problems? Email or call 0860 52 52 00.